跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 46,423 条关于
“Supernus Pharmaceuticals Inc”
全部
46,423
临床试验
11,577
药物
3,158
机构
7,496
资讯
24,192
2年前
FDA Issues Complete Response Letter for Supernus' SPN-830 (Apomorphine) in Parkinson's Disease
去年
Global Cerebral Palsy Clinical Trial Landscape Assessed in New 2024 Review
去年
FDA Updates Viloxazine Label with New Pharmacodynamic and Lactation Data for ADHD Treatment
去年
Knight Therapeutics Seeks Approval for Qelbree® (viloxazine) in Canada for ADHD Treatment
去年
TBI Therapeutics Advance Through Clinical Trials: SanBio's SB623 Receives Sakigake Designation
2个月前
Supernus Marks Five Years of Qelbree: The First Novel Non-Stimulant ADHD Treatment in Over a Decade
去年
FDA Gears Up for Critical Decisions on Alzheimer's, Breast Cancer, and Neurological Therapies in Early 2025
去年
Supernus Pharmaceuticals Acquires Sage Therapeutics for $795 Million, Strengthening Neuropsychiatry Portfolio
去年
Supernus Pharmaceuticals Acquires Sage Therapeutics for Up to $795 Million, Securing Postpartum Depression Drug Zurzuvae
去年
Virios Therapeutics and Wex Pharmaceuticals Merge to Form Dogwood Therapeutics, Advancing Novel Pain and Viral Therapies
第 1 页，共 2420 页
上一页
下一页
